NCT03587922 is a NA clinical trial of Fantom in Coronary Artery Disease, sponsored by REVA Medical, Inc..

Who is sponsoring NCT03587922?

NCT03587922 is sponsored by REVA Medical, Inc..

What drugs are being tested in NCT03587922?

Interventions in NCT03587922: Fantom.

What condition does NCT03587922 study?

NCT03587922 studies Coronary Artery Disease.

Is NCT03587922 still recruiting?

NCT03587922 is currently recruiting now. Last updated 14 June 2024.

Last reviewed 2024-06-14 · How we verify

NCT03587922

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FANTOM Post Market Clinical Trial

Recruiting now NA Last updated 14 June 2024

What this trial tests

NA trial testing Fantom in Coronary Artery Disease in 1,500 participants. Currently enrolling.

Timeline

1 May 2018

Primary endpoint
1 May 2025

1 May 2025

Quick facts

Lead sponsor	REVA Medical, Inc.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1,500
Start date	1 May 2018
Primary completion	1 May 2025
Estimated completion	1 May 2025
Sites	10 locations across Austria, Switzerland, Germany

Drugs / interventions tested

Fantom

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

REVA Medical, Inc.

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Post Market study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other REVA Medical, Inc. trials

Trials by the same sponsor.

NCT05406622 — MOTIV BTK Randomized Controlled Trial · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03587922 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by REVA Medical, Inc.
Last refreshed: 14 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03587922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing